Biology of premature ageing in survivors of cancer

ESMO Open

Volumn 2, Issue 5, 2017, Pages

  Cupit Link, Margaret C ^a   Kirkland, James L ^a   Ness, Kirsten K ^b   Armstrong, Gregory T ^b   Tchkonia, Tamar ^a   Lebrasseur, Nathan K ^a   Armenian, Saro H ^c   Ruddy, Kathryn J ^a   Hashmi, Shahrukh K ^a  

^a MAYO CLINIC   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

aging; anticancer therapeutics; long term side effects

Indexed keywords

EID: 85041999978     PISSN: None     EISSN: 20597029     Source Type: Journal    
DOI: 10.1136/esmoopen-2017-000250     Document Type: Review

References (83)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.
2. Oeffinger KC, Mertens AC, Sklar CA, et al. Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82.
3. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: A summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2328-38.
4. Arora M, Sun CL, Ness KK, et al. Physiologic frailty in nonelderly hematopoietic cell transplantation patients: results from the bone marrow transplant survivor study. JAMA Oncol 2016;2:1277-1286.
5. Armstrong GT, Chen Y, Yasui Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med 2016;374:833-42.
6. Phillips SM, Padgett LS, Leisenring WM, et al. Survivors of childhood cancer in the United States: prevalence and burden of morbidity. Cancer Epidemiol Biomarkers Prev 2015;24:653-63.
7. From cancer patient to cancer survivor: lost in transition. In: Hewitt MGS, Stovall E, eds. Washington, DC: National Academies Press.
8. Cupit MC, Duncan C, Savani BN, et al. Childhood to adult transition and long-term follow-up after blood and marrow transplantation. Bone Marrow Transplant 2016;51:176-81.
9. Hashmi S, Carpenter P, Khera N, et al. Lost in transition: The essential need for long-term follow-up clinic for blood and marrow transplantation survivors. Biol Blood Marrow Transplant 2015;21:225-32.
10. López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell 2013;153:1194-217.
11. Armstrong GT, Kawashima T, Leisenring W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 2014;32:1218-27.
12. Syrjala KL, Langer SL, Abrams JR, et al. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol 2005;23:6596-606.
13. Bhakta N, Liu Q, Yeo F, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: An analysis from the St Jude Lifetime Cohort Study. Lancet Oncol 2016;17:1325-34.
14. Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 2010;102:1083-95.
15. Reulen RC, Frobisher C, Winter DL, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA 2011;305:2311-9.
16. Olsen JH, Möller T, Anderson H, et al. Lifelong cancer incidence in 47, 697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst 2009;101:806-13.
17. Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: An update. Blood Cancer J 2011;1:e16.
18. Mitnitski AB, Graham JE, Mogilner AJ, et al. Frailty, fitness and latelife mortality in relation to chronological and biological age. BMC Geriatr 2002;2:1.
19. Kirkwood TB, Austad SN. Why do we age Nature 2000;408:233-8.
20. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: Toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc 2006;54:991-1001.
21. Buta BJ, Walston JD, Godino JG, et al. Frailty assessment instruments: systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res Rev 2016;26:53-61.
22. Sternberg SA, Wershof Schwartz A, Karunananthan S, et al. The identification of frailty: A systematic literature review. J Am Geriatr Soc 2011;59:2129-38.
23. Collard RM, Boter H, Schoevers RA, et al. Prevalence of frailty in community-dwelling older persons: A systematic review. J Am Geriatr Soc 2012;60:1487-92.
24. Arora M, Sun C-L, Ness KK, et al. Physiologic frailty among hematopoietic cell transplantation (HCT) survivors suggests accelerated aging and is a predictor for premature mortality: A report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood 2015;126:739.
25. Sun CL, Kersey JH, Francisco L, et al. Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study. Biol Blood Marrow Transplant 2013;19:1073-80.
26. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238:787-93.
27. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
28. Mertens AC, Yong J, Dietz AC, et al. Conditional survival in pediatric malignancies: Analysis of data from the childhood cancer survivor study and the surveillance, epidemiology, and end results program. Cancer 2015;121:1108-17.
29. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult longterm survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. JAMA 2003;290:1583-92.
30. Hudson MM, Oeffinger KC, Jones K, et al. Age-dependent changes in health status in the Childhood Cancer Survivor cohort. J Clin Oncol 2015;33:479-91.
31. Ness KK, Krull KR, Jones KE, et al. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: A report from the St Jude Lifetime cohort study. J Clin Oncol 2013;31:4496-503.
32. Armstrong GT, Reddick WE, Petersen RC, et al. Evaluation of memory impairment in aging adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiotherapy. J Natl Cancer Inst 2013;105:899-907.
33. Armenian SH, Sun CL, Kawashima T, et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: A report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood 2011;118:1413-20.
34. Smith M, Abrams J, Trimble EL, et al. Dose intensity of chemotherapy for childhood cancers. Oncologist 1996;1:293-304.
35. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 2014;124:344-53.
36. Maccormick RE. Possible acceleration of aging by adjuvant chemotherapy: A cause of early onset frailty Med Hypotheses 2006;67:212-5.
37. Christensen JF, Jones LW, Andersen JL, et al. Muscle dysfunction in cancer patients. Ann Oncol 2014;25:947-58.
38. Ferrando AA, Lane HW, Stuart CA, et al. Prolonged bed rest decreases skeletal muscle and whole body protein synthesis. Am J Physiol 1996;270(Pt 1):E627-33.
39. Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am 2010;43:753-68.
40. Tchkonia T, Zhu Y, van Deursen J, et al. Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. J Clin Invest 2013;123:966-72.
41. Counter CM. The roles of telomeres and telomerase in cell life span. Mutat Res 1996;366:45-63.
42. Boonekamp JJ, Simons MJ, Hemerik L, et al. Telomere length behaves as biomarker of somatic redundancy rather than biological age. Aging Cell 2013;12:330-2.
43. Wentzensen IM, Mirabello L, Pfeiffer RM, et al. The association of telomere length and cancer: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2011;20:1238-50.
44. Shay J, Wright W, Werbin H. Loss of telomeric DNA during aging may predispose cells to cancer (review). Int J Oncol 1993;3:559-63.
45. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
46. Xu M, Palmer AK, Ding H, et al. Targeting senescent cells enhances adipogenesis and metabolic function in old age. Elife 2015;4:e12997.
47. de Lange T, Shiue L, Myers RM, et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990;10:518-27.
48. Xu M, Tchkonia T, Ding H, et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc Natl Acad Sci U S A 2015;112:E6301-E6310.
49. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
50. Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999;5:1164-70.
51. Buseman CM, Wright WE, Shay JW. Is telomerase a viable target in cancer Mutat Res 2012;730:90-7.
52. Franco S, Ozkaynak MF, Sandoval C, et al. Telomere dynamics in childhood leukemia and solid tumors: A follow-up study. Leukemia 2003;17:401-10.
53. Zhang RG, Zhang RP, Wang XW, et al. Effects of cisplatin on telomerase activity and telomere length in BEL-7404 human hepatoma cells. Cell Res 2002;12:55-62.
54. Hao LY, Armanios M, Strong MA, et al. Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 2005;123:1121-31.
55. Harrison DE. Proliferative capacity of erythropoietic stem cell lines and aging: An overview. Mech Ageing Dev 1979;9:409-26.
56. Beauséjour C. Bone marrow-derived cells: The influence of aging and cellular senescence. In: Kauser K, Zeiher A-M, eds. Bone marrowderived progenitors Berlin, Heidelberg Springer, 2007:67-88.
57. Akiyama M, Hideshima T, Hayashi T, et al. Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 2003;63:18-21.
58. Wynn RF, Cross MA, Hatton C, et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 1998;351:178-81.
59. Chabner BA, Myers CE, Coleman CN, et al. The clinical pharmacology of antineoplastic agents. N Engl J Med Overseas Ed 1975;292:1107-13.
60. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992;19:47-84.
61. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 2005;102:10604-9.
62. Fraga MF, Agrelo R, Esteller M. Cross-talk between aging and cancer: The epigenetic language. Ann N Y Acad Sci 2007;1100:60-74.
63. Wang Y, Scheiber MN, Neumann C, et al. MicroRNA regulation of ionizing radiation-induced premature senescence. Int J Radiat Oncol Biol Phys 2011;81:839-48.
64. Li G, Luna C, Qiu J, et al. Alterations in microRNA expression in stress-induced cellular senescence. Mech Ageing Dev 2009;130(11-12):731-41.
65. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003;63:2705-15.
66. Siddiqui MS, François M, Fenech MF, et al. Persistent H2AX: A promising molecular marker of DNA damage and aging. Mutat Res Rev Mutat Res 2015;766:1-19.
67. te Poele RH, Okorokov AL, Jardine L, et al. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002;62:1876-83.
68. Lobetti-Bodoni C, Ferrero D, Genuardi E, et al. Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. Mech Ageing Dev 2012;133:479-88.
69. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. The Lancet 2014;384:2027-35.
70. Lee JJ, Nam CE, Cho SH, et al. Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy. Ann Hematol 2003;82:492-5.
71. Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 2013;39:444-56.
72. Nyce J. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res 1989;49:5829-36.
73. Johnson AA, Akman K, Calimport SR, et al. The role of DNA methylation in aging, rejuvenation, and age-related disease. Rejuvenation Res 2012;15:483-94.
74. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007;104:15805-10.
75. Piegari E, De Angelis A, Cappetta D, et al. Doxorubicin induces senescence and impairs function of human cardiac progenitor cells. Basic Res Cardiol 2013;108:334.
76. Lahav M, Uziel O, Kestenbaum M, et al. Nonmyeloablative conditioning does not prevent telomere shortening after allogeneic stem cell transplantation. Transplantation 2005;80:969-76.
77. Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 2009;114:2236-43.
78. Townsley DM, Dumitriu B, Liu D, et al. Danazol treatment for telomere diseases. N Engl J Med 2016;374:1922-31.
79. Justice J, Miller JD, Newman JC, et al. Frameworks for proof-ofconcept clinical trials of interventions that target fundamental aging processes. J Gerontol A Biol Sci Med Sci 2016;71:1415-23.
80. LeBrasseur NK, Tchkonia T, Kirkland JL. Cellular senescence and the biology of aging, disease, and frailty. Nestle Nutr Inst Workshop Ser 2015;83:11-18.
81. Kirkland JL, Tchkonia T. Clinical strategies and animal models for developing senolytic agents. Exp Gerontol 2015;68:19-25.
82. Zhu Y, Armstrong JL, Tchkonia T, et al. Cellular senescence and the senescent secretory phenotype in age-related chronic diseases. Curr Opin Clin Nutr Metab Care 2014;17:324-8.
83. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961;25:585-621.